AbbVie Announces Extension of Review for Supplemental New Drug Application of Upadacitinib for the Treatment of Moderate to Severe Atopic Dermatitis Biotech Investing
INVESTOR ACTION NOTICE: The Schall Law Firm Reminds Investors of Class Action Lawsuit Against BELLUS Health Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Biotech Investing
BLU INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff in a Securities Class Action Lawsuit Against BELLUS Health, Inc. Biotech Investing
BLU LOSS ALERT: ROSEN A TOP RANKED INVESTOR RIGHTS LAW FIRM, Encourages BELLUS Health Inc. Investors with LARGE LOSSES to Secure Counsel Before Important Deadline in Securities Class Action - BLU Biotech Investing
BLU SHAREHOLDER FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff in a Securities Class Action Lawsuit Against BELLUS Health, Inc. Biotech Investing
BLU Investor Notice: Rosen, A Respected and Leading Firm, Encourages BELLUS Health Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - BLU Biotech Investing
Kite Submits Supplemental Biologics License Application to U.S. Food and Drug Administration for Tecartus® in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Biotech Investing
Cardiol Therapeutics Announces Filing of 2020 Year-End Financial Statements and MD&A Biotech Investing
New England Journal of Medicine Publishes 24-Week Results from Phase 3 Study Evaluating RINVOQ in Psoriatic Arthritis Biotech Investing
